Novartis Ag Adr (NVS)

Oct 24, 2025

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases - GlobeNewswire Inc.

Oct 24, 2025

Oct 20, 2025

Will Positive Regulatory Updates Further Boost INCY Stock? - The Globe and Mail

Oct 20, 2025

Oct 17, 2025

Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial - Sahm

Oct 17, 2025

Oct 16, 2025

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity - Sahm

Oct 16, 2025

Oct 16, 2025

Novartis Strengthens Kidney Disease Pipeline With Promising Data - Sahm

Oct 16, 2025

Oct 15, 2025

Next-Generation Targeted Therapies Reshape Precision Oncology Landscape - Sahm

Oct 15, 2025

Oct 14, 2025

Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears - Sahm

Oct 14, 2025

Oct 13, 2025

Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio? - The Globe and Mail

Oct 13, 2025

Oct 11, 2025

UBS Reaffirms Their Hold Rating on Novartis AG (NOVN) - The Globe and Mail

Oct 11, 2025

Oct 08, 2025

Should You Buy Novartis Stock Before October 28? - Barchart.com

Oct 08, 2025

Oct 08, 2025

Barclays Reaffirms Their Sell Rating on Novartis AG (NOVN) - The Globe and Mail

Oct 08, 2025

Oct 04, 2025

2 Surefire Dividend Stocks to Buy for the Long Haul - sharewise.com

Oct 04, 2025

Oct 03, 2025

Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance (NYSE:NVS) - Seeking Alpha

Oct 03, 2025

Sep 30, 2025

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) - Ariva

Sep 30, 2025

Sep 29, 2025

Pharma's Direct-To-Patient Wave Hits Novartis Next - Sahm

Sep 29, 2025

Sep 29, 2025

Novartis announces commencement of tender offer to acquire Tourmaline Bio - Novartis

Sep 29, 2025

Sep 25, 2025

Trump's New Tariff Barrage Targets Drugs, Trucks, Cabinets: President Says Move Will Protect Manufacturers From 'Unfair Outside Competition' - Sahm

Sep 25, 2025

Sep 25, 2025

Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move? - Sahm

Sep 25, 2025

Sep 24, 2025

Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies - Sahm

Sep 24, 2025

Sep 19, 2025

INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - The Globe and Mail

Sep 19, 2025

Sep 15, 2025

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments - Sahm

Sep 15, 2025

Sep 13, 2025

Novartis (NVS) was downgraded to a Sell Rating at Goldman Sachs - The Globe and Mail

Sep 13, 2025

Sep 12, 2025

Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concer - GuruFocus

Sep 12, 2025

Sep 12, 2025

Novartis cut to Sell at Goldman Sachs on near-term risks (NVS:NYSE) - Seeking Alpha

Sep 12, 2025

Sep 11, 2025

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer - The Globe and Mail

Sep 11, 2025

Sep 10, 2025

5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds - The Globe and Mail

Sep 10, 2025

Sep 09, 2025

Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver - sharewise.com

Sep 09, 2025

Sep 09, 2025

Novartis strikes $1.4bn deal for Tourmaline Bio - Proactive financial news

Sep 09, 2025

Sep 09, 2025

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) - Novartis

Sep 09, 2025

Sep 04, 2025

Palantir Deepens Industry Ties As Lear And Lumen Embrace Its AI Platforms - Sahm

Sep 04, 2025

Sep 04, 2025

Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity? - The Globe and Mail

Sep 04, 2025

Sep 03, 2025

Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.

Sep 03, 2025